Skip to main content

Table 1 Clinical information about the patients

From: Predictors of euthyreosis in hyperthyroid patients treated with radioiodine 131I: a retrospective study

  Group 1 (n = 81) Group 2 (n = 52) Group 3 (n = 11) p-value GD patients (n = 63) TMNG patients (n = 81) p
Males [n, %] 21(25.9) 21 (40.4) 4 (36.4) 0.2 16 (25.4) 30 (37) 0.23
Age [years] 53.5 ± 16.3 67.3 ± 12.7 50.9 ± 16.4 0.00001 48.6 ± 15.5 65.8 ± 12.9 0.000001
Graves’ disease [n, %] 48 (59.3) 8 (15.4) 7 (63.6) 0.000001    
Thyroidectomy in history [n, %] 6 (7.4) 0 (0) 1 (9.1) 0.12 2 (3.2) 5 (6.2) 0.41
Thyrostatic drugs used before RAI treatment [n, %] 20 (24.7) 15 (28.8) 6 (54.5) 0.12 13 (20.6) 28 (34.6) 0.06
Beta-blockers used before RAI treatment [n, %] 19 (23.4) 19 (36.5) 2 (18.2) 0.19 11 (17.5) 29 (35.8) 0.05
Steroids used before RAI treatment [n, %] 3 (3.7) 2 (3.8) 0 (0) 0.8 4 (6.3) 1 (1.2) 0.09
Orbitopathy [n, %] 1 (1.2) 0 (0) 0 (0) 0.67 1 (1.6) 0 (0) 0.26
Thyroid volume before RAI treatment [cm3] 22.6 ± 13 41.9 ± 22.2 54 ± 31.7 0.00001 24.3 ± 19.6 37.8 ± 21.3 0.000004
Thyroid volume 6 months after RAI treatment [cm3] 8.4 ± 12.6 23 ± 16.4 29.7 ± 20.1 0.00001 7.5 ± 9.1 21.4 ± 18.6 0.000001
Diffused nodules [n, %] 39 (54.9) 44 (84.6) 5 (50) 0.001 N/A   
‘Cold’ nodules 1 (1.2) 2 (3.8) 1 (9) 0.28 1 (1.6) 3 (3.7) 0.44
Iodine uptake [%] 36.4 ± 13.4 30.2 ± 11.3 54.3 ± 16.6 0.00001 40.1 ± 14.3 32.2 ± 13.4 0.0009
Uneven iodine distribution [n, %] 18 (22.2) 26 (50) 4 (36.4) 0.004 4 (6.3) 44 (54.3) 0.000001
Inferior poles of the thyroid lobes reaching jugular incision [n, %] 3 (3.7) 10 (19.2) 3 (27.3) 0.006 3 (4.8) 13 (16) 0.03
131I dose [MBq] 638.5 ± 44.2 658.1 ± 46.4 657.8 ± 64.8 0.035 624 ± 34.9 664.9 ± 48.4 0.00001
TSH concentration at presentation [μIU/ml] 1.5 ± 2.6 0.9 ± 1.7 0.6 ± 1 0.04 1.46 ± 2.9 1.08 ± 1.54 0.79
fT3 concentration at presentation [pg/ml] 4.1 ± 1.3 3.9 ± 1.6 5.6 ± 4.3 0.48 4.2 ± 1.9 4 ± 1.6 0.39
fT4 concentration at presentation [ng/ml] 5.5 ± 7.1 3.7 ± 5.1 2.8 ± 4.2 0.44 5.4 ± 6.8 4.1 ± 5.9 0.49
TSH concentration 6 months after RAI treatment [μIU/ml] 4.3 ± 5.7 2.3 ± 3.6 0.2 ± 0.25 0.00001 3.9 ± 6.5 2.7 ± 3.3 0.1
fT3 concentration 6 months after RAI treatment [pg/ml] 3.5 ± 1.1 3.9 ± 1.8 4.6 ± 2.3 0.79 3.8 ± 1.7 3.9 ± 0.9 0.65
fT4 concentration 6 months after RAI treatment [ng/ml] 3.4 ± 6.2 2.2 ± 3.3 1.9 ± 2 0.01 3.7 ± 6.6 2.1 ± 3.4 0.03
  1. Patients have been assigned to the groups, based on the outcome of the RAI therapy after 12 months of follow-up. Group 1 – hypothyroid, group 2 – euthyroid, group 3 – hyperthyroid. Patients with GD and TMNG have been compared. N/A not applicable